DIHYDROPYRANOPYRIMIDINES FOR THE TREATMENT OF VIRAL INFECTIONS

• US 20190322678A1
• Filed: 06/30/2017
• Published: 10/24/2019
• Est. Priority Date: 07/01/2016
• Status: Active Grant

• Current Assignee: Janssen Sciences Ireland Unlimited Company (Johnson & Johnson)
• Original Assignee: Janssen Sciences Ireland Unlimited Company (Johnson & Johnson)
• Inventors: JONCKERS, Tim Hugo Maria, RABOISSON, Pierre Jean-Marie Bernard, GUILLEMONT, Jerome Emile Georges, MC GOWAN, David Craig, EMBRECHTS, Werner Constant Johan, COOYMANS, Ludwig Paul, CALMUS, Laurent
• Granted Patent: US 11,053,256 B2
• Time in Patent Office: Days
• CPC Class Codes: A61P 31/02 Local antiseptics
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07D 491/052 the oxygen-containing ring being six-membered

Abstract

This invention relates to dihydropyranopynmidine derivatives, processes for their preparation, pharmaceutical compositions, and their use in treating viral infections.

Claims

1. A compound of formula (I), (II) or (III) having the structure

2. A compound according to claim 1 having the structure

3. A pharmaceutical composition comprising a compound of formula (I), (II) or (III) or a pharmaceutically acceptable salt, tautomer(s), stereo-isomeric forms, solvate or polymorph thereof according to claim 1 or any of the structures according to claim 2 together with one or more pharmaceutically acceptable excipients, diluents or carriers.

4. A compound of formula (I), (II) or (III) or a pharmaceutically acceptable salt, tautomer(s), stereo-isomeric forms, solvate or polymorph thereof according to claim 1 or a pharmaceutical composition according to claim 3 for use as a medicament.

5. A compound of formula (I), (II) or (III) or a pharmaceutically acceptable salt, tautomer(s), stereo-isomeric forms, solvate or polymorph thereof according to claim 1, or a pharmaceutical composition according to claim 3 for use in the treatment of a disorder in which the modulation of TLR7 and/or TLR8 is involved, preferably TLR8.